Login
AN2 Therapeutics, Inc. logo

AN2 Therapeutics, Inc.

an2therapeutics.com

What Do They Do?

Develops boron-based small-molecule drug candidates for patients with blood disorders, infectious diseases and cancer.

How Are They Changing?

Broader disease focus The earlier report centered on infectious-disease treatments, especially epetraborole for MAC lung disease. The latest report describes development and research across hematologic diseases, infectious diseases and oncology.

Beyond MAC lung disease The earlier report focused epetraborole development on treatment-refractory MAC lung disease and planned expansion to other NTM infections. The latest report also describes epetraborole development for polycythemia vera and M. abscessus lung disease, alongside a separate Chagas disease candidate.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support